Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...
The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...
Hosted on MSN
Enzalutamide + Leuprolide Boosts Overall Survival for Prostate Cancer With High Recurrence Risk
THURSDAY, Oct. 23, 2025 (HealthDay News) -- The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical ...
Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial In men with prostate cancer, bicalutamide monotherapy increases bone mineral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback